Congo Ebola Outbreak: Merck Ervebo Vaccine, Gilead Remdesivir Eyed for Wider Use

Merck’s Ebola vaccine and Gilead’s Ebola antiviral are being expanded for use in eastern DRC to curb the fastest-growing Ebola outbreak on record. The news is operationally significant for public-health response, but it is unlikely to materially move markets near term.

Analysis

Merck’s Ebola vaccine and Gilead’s Ebola antiviral are being expanded for use in eastern DRC to curb the fastest-growing Ebola outbreak on record. The news is operationally significant for public-health response, but it is unlikely to materially move markets near term.